Sign In
Buy BLCO
$14.87
-0.110 (-0.734%)
At Close: Jun 03, 2026
Bausch + Lomb Corporation (BLCO) Q2 2025 Earnings Call Transcript
09:33pm, Wednesday, 30'th Jul 2025
Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Brenton L. Saunders - CEO & Chairman George Gadkowski - Corporate Participant Osam
Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say
10:36am, Wednesday, 30'th Jul 2025
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall St
Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates
09:11am, Wednesday, 30'th Jul 2025
Bausch + Lomb (BLCO) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.13 per share a year ago.
Bausch + Lomb Announces Second-Quarter 2025 Results
06:57am, Wednesday, 30'th Jul 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-qua
New Strong Sell Stocks for July 30th
06:41am, Wednesday, 30'th Jul 2025
ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.
New Strong Sell Stocks for July 24th
06:06am, Thursday, 24'th Jul 2025
COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 23'rd Jul 2025
Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch + Lomb Combines Patient Voices and New Survey Insights to Combat Persistent Misconceptions about Dry Eye
07:00am, Tuesday, 01'st Jul 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today launched “Eyes Tell th
Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13
06:58am, Monday, 30'th Jun 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarte
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Ba
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning th
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Comp
Bausch + Lomb Announces Pricing of Upsized Senior Secured Notes Offering
04:30pm, Wednesday, 18'th Jun 2025
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to
